Myovant Sciences Net Income 2017-2022 | MYOV

Myovant Sciences net income from 2017 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Myovant Sciences Annual Net Income
(Millions of US $)
2022 $-206
2021 $-255
2020 $-289
2019 $-274
2018 $-143
2017 $-83
2016 $-2
Myovant Sciences Quarterly Net Income
(Millions of US $)
2022-12-31 $-58
2022-09-30 $-46
2022-06-30 $-21
2022-03-31 $-59
2021-12-31 $-63
2021-09-30 $-22
2021-06-30 $-62
2021-03-31 $-81
2020-12-31 $-74
2020-09-30 $-67
2020-06-30 $-33
2020-03-31 $-65
2019-12-31 $-86
2019-09-30 $-71
2019-06-30 $-68
2019-03-31 $-75
2018-12-31 $-71
2018-09-30 $-66
2018-06-30 $-62
2018-03-31 $-48
2017-12-31 $-42
2017-09-30 $-30
2017-06-30 $-23
2017-03-31 $-22
2016-12-31 $-8
2016-09-30 $-35
2016-06-30 $-19
2016-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.613B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00